Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Fetal Concentrations of Budesonide and Fluticasone Propionate: a Study in Mice.

Zaidi S, Chen MJ, Lee DT, Neubart E, Ewing P, Miller-Larsson A, Hochhaus G.

AAPS J. 2019 Apr 16;21(4):53. doi: 10.1208/s12248-019-0313-2.

PMID:
30993489
2.

Glucocorticoid-driven transcriptomes in human airway epithelial cells: commonalities, differences and functional insight from cell lines and primary cells.

Mostafa MM, Rider CF, Shah S, Traves SL, Gordon PMK, Miller-Larsson A, Leigh R, Newton R.

BMC Med Genomics. 2019 Jan 31;12(1):29. doi: 10.1186/s12920-018-0467-2.

3.

Bacterial regulation of macrophage bacterial recognition receptors in COPD are differentially modified by budesonide and fluticasone propionate.

Provost KA, Smith M, Miller-Larsson A, Gudleski GD, Sethi S.

PLoS One. 2019 Jan 24;14(1):e0207675. doi: 10.1371/journal.pone.0207675. eCollection 2019.

4.

Low-Dose Budesonide/Formoterol Counteracts Airway Inflammation and Improves Lung Function in Chronic Obstructive Pulmonary Disease.

Hakim A, Khan Y, Esteban I, Meah S, Miller-Larsson A, Barnes PJ, Usmani OS.

Am J Respir Crit Care Med. 2019 Mar 1;199(5):662-664. doi: 10.1164/rccm.201808-1590LE. No abstract available.

5.

Long-Acting β2-Adrenoceptor Agonists Enhance Glucocorticoid Receptor (GR)-Mediated Transcription by Gene-Specific Mechanisms Rather Than Generic Effects via GR.

Rider CF, Altonsy MO, Mostafa MM, Shah SV, Sasse S, Manson ML, Yan D, Kärrman-Mårdh C, Miller-Larsson A, Gerber AN, Giembycz MA, Newton R.

Mol Pharmacol. 2018 Sep;94(3):1031-1046. doi: 10.1124/mol.118.112755. Epub 2018 Jun 29.

PMID:
29959223
6.

Effects of fluticasone propionate and budesonide on the expression of immune defense genes in bronchial epithelial cells.

van den Berge M, Jonker MR, Miller-Larsson A, Postma DS, Heijink IH.

Pulm Pharmacol Ther. 2018 Jun;50:47-56. doi: 10.1016/j.pupt.2018.04.002. Epub 2018 Apr 5.

PMID:
29627483
7.

Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD.

Janson C, Stratelis G, Miller-Larsson A, Harrison TW, Larsson K.

Int J Chron Obstruct Pulmon Dis. 2017 Oct 19;12:3055-3064. doi: 10.2147/COPD.S143656. eCollection 2017. Review.

8.

An inhaled dose of budesonide induces genes involved in transcription and signaling in the human airways: enhancement of anti- and proinflammatory effector genes.

Leigh R, Mostafa MM, King EM, Rider CF, Shah S, Dumonceaux C, Traves SL, McWhae A, Kolisnik T, Kooi C, Slater DM, Kelly MM, Bieda M, Miller-Larsson A, Newton R.

Pharmacol Res Perspect. 2016 Jul 12;4(4):e00243. doi: 10.1002/prp2.243. eCollection 2016 Aug.

9.

Protein tyrosine phosphatase PTP-RR regulates corticosteroid sensitivity.

Kobayashi Y, Ito K, Kanda A, Tomoda K, Miller-Larsson A, Barnes PJ, Mercado N.

Respir Res. 2016 Mar 24;17:30. doi: 10.1186/s12931-016-0349-0.

10.

Cytokine-induced loss of glucocorticoid function: effect of kinase inhibitors, long-acting β(2)-adrenoceptor [corrected] agonist and glucocorticoid receptor ligands.

Rider CF, Shah S, Miller-Larsson A, Giembycz MA, Newton R.

PLoS One. 2015 Jan 27;10(1):e0116773. doi: 10.1371/journal.pone.0116773. eCollection 2015. Erratum in: PLoS One. 2015;10(5):e0128728.

11.

Budesonide and formoterol effects on rhinovirus replication and epithelial cell cytokine responses.

Bochkov YA, Busse WW, Brockman-Schneider RA, Evans MD, Jarjour NN, McCrae C, Miller-Larsson A, Gern JE.

Respir Res. 2013 Oct 4;14:98. doi: 10.1186/1465-9921-14-98.

12.

Anti-inflammatory effects of budesonide in human lung fibroblast are independent of histone deacetylase 2.

Wang X, Nelson A, Weiler ZM, Patil A, Sato T, Kanaji N, Nakanishi M, Michalski J, Farid M, Basma H, Levan TD, Miller-Larsson A, Wieslander E, Muller KC, Holz O, Magnussen H, Rabe KF, Liu X, Rennard SI.

J Inflamm Res. 2013 Aug 20;6:109-19. doi: 10.2147/JIR.S43736. eCollection 2013.

13.

Effect of budesonide on fibroblast-mediated collagen gel contraction and degradation.

Fang Q, Schulte NA, Kim H, Kobayashi T, Wang X, Miller-Larsson A, Wieslander E, Toews ML, Liu X, Rennard SI.

J Inflamm Res. 2013;6:25-33. doi: 10.2147/JIR.S35136. Epub 2013 Feb 27.

14.

Modulation of transcriptional responses by poly(I:C) and human rhinovirus: effect of long-acting β₂-adrenoceptor agonists.

Rider CF, Miller-Larsson A, Proud D, Giembycz MA, Newton R.

Eur J Pharmacol. 2013 May 15;708(1-3):60-7. doi: 10.1016/j.ejphar.2013.02.056. Epub 2013 Mar 20.

PMID:
23523474
15.

Tissue accumulation kinetics of ciclesonide-active metabolite and budesonide in mice.

Mårs U, d'Argy R, Hallbeck K, Miller-Larsson A, Edsbäcker S.

Basic Clin Pharmacol Toxicol. 2013 Jun;112(6):401-11. doi: 10.1111/bcpt.12043. Epub 2013 Feb 7.

16.

Pharmacological modulation of the bradykinin-induced differentiation of human lung fibroblasts: effects of budesonide and formoterol.

Sabatini F, Petecchia L, Usai C, Silvestri M, Rossi GA, Miller-Larsson A, Ricciardolo FL.

J Asthma. 2012 Dec;49(10):1004-11. doi: 10.3109/02770903.2012.729633. Epub 2012 Oct 22.

17.

Altered lung function relates to inflammation in an acute LPS mouse model.

Håkansson HF, Smailagic A, Brunmark C, Miller-Larsson A, Lal H.

Pulm Pharmacol Ther. 2012 Oct;25(5):399-406. doi: 10.1016/j.pupt.2012.08.001. Epub 2012 Aug 16.

PMID:
22975080
18.

Lung epithelial-C/EBPβ contributes to LPS-induced inflammation and its suppression by formoterol.

Roos AB, Barton JL, Miller-Larsson A, Dahlberg B, Berg T, Didon L, Nord M.

Biochem Biophys Res Commun. 2012 Jun 22;423(1):134-9. doi: 10.1016/j.bbrc.2012.05.096. Epub 2012 May 24.

PMID:
22634316
19.

Increased corticosteroid sensitivity by a long acting β2 agonist formoterol via β2 adrenoceptor independent protein phosphatase 2A activation.

Kobayashi Y, Mercado N, Miller-Larsson A, Barnes PJ, Ito K.

Pulm Pharmacol Ther. 2012 Jun;25(3):201-7. doi: 10.1016/j.pupt.2012.02.005. Epub 2012 Mar 2.

PMID:
22401993
20.

The β2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts.

Lamyel F, Warnken-Uhlich M, Seemann WK, Mohr K, Kostenis E, Ahmedat AS, Smit M, Gosens R, Meurs H, Miller-Larsson A, Racké K.

Naunyn Schmiedebergs Arch Pharmacol. 2011 Aug;384(2):133-45. doi: 10.1007/s00210-011-0655-5. Epub 2011 May 21.

PMID:
21603974
21.

TGFβ-induced matrix production by bronchial fibroblasts in asthma: budesonide and formoterol effects.

Todorova L, Bjermer L, Westergren-Thorsson G, Miller-Larsson A.

Respir Med. 2011 Sep;105(9):1296-307. doi: 10.1016/j.rmed.2011.03.020. Epub 2011 Apr 21.

22.

Relationship between matrix production by bronchial fibroblasts and lung function and AHR in asthma.

Todorova L, Bjermer L, Miller-Larsson A, Westergren-Thorsson G.

Respir Med. 2010 Dec;104(12):1799-808. doi: 10.1016/j.rmed.2010.06.015. Epub 2010 Jul 15.

23.

Budesonide prevents cytokine-induced decrease of the relaxant responses to formoterol and terbutaline, but not to salmeterol, in mouse trachea.

Adner M, Larsson B, Säfholm J, Naya I, Miller-Larsson A.

J Pharmacol Exp Ther. 2010 Apr;333(1):273-80. doi: 10.1124/jpet.109.156224. Epub 2010 Jan 8.

PMID:
20061444
24.

Budesonide/formoterol effects on metalloproteolytic balance in TGFbeta-activated human lung fibroblasts.

Todorova L, Gürcan E, Westergren-Thorsson G, Miller-Larsson A.

Respir Med. 2009 Nov;103(11):1755-63. doi: 10.1016/j.rmed.2009.03.018. Epub 2009 Apr 17.

25.

Sensitivity of disease parameters to flexible budesonide/formoterol treatment in an allergic rat model.

Brange C, Smailagic A, Jansson AH, Middleton B, Miller-Larsson A, Taylor JD, Silberstein DS, Lal H.

Pulm Pharmacol Ther. 2009 Feb;22(1):20-6. doi: 10.1016/j.pupt.2008.10.011. Epub 2008 Nov 12.

PMID:
19041412
26.

Combined budesonide/formoterol therapy in conjunction with allergen avoidance ameliorates house dust mite-induced airway remodeling and dysfunction.

Johnson JR, Pacitto SR, Wong J, Archer EW, Eirefelt S, Miller-Larsson A, Jordana M.

Am J Physiol Lung Cell Mol Physiol. 2008 Nov;295(5):L780-8. doi: 10.1152/ajplung.90229.2008. Epub 2008 Sep 5.

27.

Differences in endogenous esterification and retention in the rat trachea between budesonide and ciclesonide active metabolite.

Lexmüller K, Gullstrand H, Axelsson BO, Sjölin P, Korn SH, Silberstein DS, Miller-Larsson A.

Drug Metab Dispos. 2007 Oct;35(10):1788-96. Epub 2007 Jul 12.

PMID:
17627977
28.

Anti-inflammatory activity of beta2-agonists in primary lung epithelial cells is independent of glucocorticoid receptor.

Lovén J, Svitacheva N, Jerre A, Miller-Larsson A, Korn SH.

Eur Respir J. 2007 Nov;30(5):848-56. Epub 2007 Jun 27.

29.

Cooperative inhibitory effects of budesonide and formoterol on eosinophil superoxide production stimulated by bronchial epithelial cell conditioned medium.

Persdotter S, Lindahl M, Malm-Erjefalt M, von Wachenfeldt K, Korn SH, Stevens T, Miller-Larsson A.

Int Arch Allergy Immunol. 2007;143(3):201-10. Epub 2007 Feb 9.

PMID:
17290146
30.
31.

Lung fibroblast proteoglycan production induced by serum is inhibited by budesonide and formoterol.

Todorova L, Gürcan E, Miller-Larsson A, Westergren-Thorsson G.

Am J Respir Cell Mol Biol. 2006 Jan;34(1):92-100. Epub 2005 Sep 15.

PMID:
16166747
32.

The role of intracellular esterification in budesonide once-daily dosing and airway selectivity.

Brattsand R, Miller-Larsson A.

Clin Ther. 2003;25 Suppl C:C28-41. Review.

PMID:
14642802
33.

No evidence of glucocorticosteroid-induced apoptosis of airway epithelial cells In vivo.

Miller-Larsson A, Selroos O.

Am J Respir Crit Care Med. 2002 Jun 1;165(11):1567; author reply 1567-8. No abstract available.

PMID:
12045136
34.

Gut mucosal uptake and retention characteristics contribute to the high intestinal selectivity of budesonide compared with prednisolone in the rat.

Miller-Larsson A, Gustafsson B, Persson CG, Brattsand R.

Aliment Pharmacol Ther. 2001 Dec;15(12):2019-25.

35.
36.

Prolonged airway activity and improved selectivity of budesonide possibly due to esterification.

Miller-Larsson A, Jansson P, Runström A, Brattsand R.

Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1455-61.

PMID:
11029361
37.

Adrenalectomy permits a late, local TNF-alpha release in LPS-challenged rat airways.

Miller-Larsson A, Runström A, Brattsand R.

Eur Respir J. 1999 Jun;13(6):1310-7.

38.

Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue.

Miller-Larsson A, Mattsson H, Hjertberg E, Dahlbäck M, Tunek A, Brattsand R.

Drug Metab Dispos. 1998 Jul;26(7):623-30.

PMID:
9660844
39.

Inhibition of nitric oxide synthase reduces Sephadex-induced oedema formation in the rat lung: dependence on intact adrenal function.

Andersson SE, Källström L, Malm M, Miller-Larsson A, Axelsson B.

Inflamm Res. 1995 Oct;44(10):418-22.

PMID:
8564517
40.

Attenuation of bradykinin-induced mucosal inflammation by topical budesonide in rat trachea.

Brattsand R, O'Donnell SR, Miller-Larsson A, Rauchle KL.

Agents Actions. 1991 Sep;34(1-2):200-2.

PMID:
1793030
41.

Native fluorescence of extravasated proteins. A new method for quantitation of macromolecular vascular leakage.

Miller-Larsson A, Brattsand R.

J Pharmacol Methods. 1991 May;25(3):251-62.

PMID:
2056754
42.

An in situ preparation of rat trachea for studying the effects of mucosally applied anti-asthma drugs on mediator-induced plasma exudation.

O'Donnell SR, Miller-Larsson A, Brattsand R, Rauchle KL.

Agents Actions Suppl. 1991;34:491-5.

PMID:
1793080
43.

Topical anti-inflammatory activity of the glucocorticoid budesonide on airway mucosa. Evidence for a "hit and run" type of activity.

Miller-Larsson A, Brattsand R.

Agents Actions. 1990 Jan;29(1-2):127-9. No abstract available.

PMID:
2327315
44.

A method of description of single muscle fibre action potential by an analytical function V(t, r).

Piotrkiewicz M, Miller-Larsson A.

Biol Cybern. 1987;56(4):237-45.

PMID:
3607099
45.

Motor unit action potential field--modelling results.

Miller-Larsson A.

Biol Cybern. 1986;53(5):307-21.

PMID:
3697402
46.
47.

A model of spatial distribution of muscle fibres of a motor unit in normal human limb muscles.

Miller-Larsson A.

Electromyogr Clin Neurophysiol. 1980 Jul-Sep;20(4-5):281-98. No abstract available.

PMID:
7418648
48.

The analysis of single EMG potentials by means of multivariate methods.

Blinowska KJ, Hausmanowa-Petrusewicz I, Miller-Larsson A, Zachara J.

Electromyogr Clin Neurophysiol. 1980 Mar-Apr;20(2):105-23. No abstract available.

PMID:
7379735

Supplemental Content

Loading ...
Support Center